Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection

被引:1
作者
Jettte, Lucie [1 ]
Bissoon-Haqqani, Seema [1 ,3 ]
Le Francois, Brice [1 ,3 ]
Maroun, Jean A. [2 ]
Birnboim, H. Chaim [1 ,3 ]
机构
[1] Ottawa Hlth Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 8L6, Canada
[2] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada
[3] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada
关键词
thymidylate synthase; resistance; 5-FU; 5-FUdR; mycoplasma;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: 5-Fluorouracil (5-FU) is an antineoplastic drug that targets thymidylate synthase (TS). Tumour cells can develop resistance to anti-TS drugs by a variety of mechanisms including up-regulation of TS protein and alterations in drug uptake and degradation. The possible mechanisms of the observed rapid development of resistance to the pyrimidine analogs 5-FUdR and 5-FU in cultured HCT116 colon cancer cells were investigated. Materials and Methods: Cell survival was determined in resistant and control HCT116 cells treated with 5-FUdR and 5-FU for 7 days. The ability of the cells to take up and metabolize these drugs was determined by Western blotting and [H-3]thymidine incorporation. Results and Conclusion: Resistant HCT116 cells were 5- and 100-fold more resistant to killing by 5-FU and 5-FUdR, respectively, than the parental cells and exhibited impaired uptake. Although the HCT116R cells were initially Mycoplasma free, a low level of Mycoplasma contamination was found in these cells after several weeks in culture. Sensitivity to 5-FUdR was restored by treatment with an anti-Mycoplasma antibiotic. Our observations emphasize the need for frequent testing for Mycoplasma contamination in any cell line under investigation for resistance to anti-TS drugs.
引用
收藏
页码:2175 / 2180
页数:6
相关论文
共 39 条
  • [1] Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance
    Agarwal, RP
    Han, T
    Fernandez, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 2001, 61 (01) : 39 - 47
  • [2] MAMMALIAN DEOXYRIBONUCLEOSIDE KINASES
    ARNER, ESJ
    ERIKSSON, S
    [J]. PHARMACOLOGY & THERAPEUTICS, 1995, 67 (02) : 155 - 186
  • [3] ARONOW B, 1985, J BIOL CHEM, V260, P6274
  • [4] The equilibrative nucleoside transporter family, SLC29
    Baldwin, SA
    Beal, PR
    Yao, SYM
    King, AE
    Cass, CE
    Young, JD
    [J]. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2004, 447 (05): : 735 - 743
  • [5] BAPAT AR, 1983, J BIOL CHEM, V258, P4130
  • [6] BERGER SH, 1988, MOL PHARMACOL, V34, P480
  • [7] BERGER SH, 1985, MOL PHARMACOL, V28, P461
  • [8] HETEROGENEITY OF HUMAN-COLON CARCINOMA
    BRATTAIN, MG
    LEVINE, AE
    CHAKRABARTY, S
    YEOMAN, LC
    WILLSON, JKV
    LONG, B
    [J]. CANCER AND METASTASIS REVIEWS, 1984, 3 (03) : 177 - 191
  • [9] Disruption of p53 in human cancer cells alters the responses to therapeutic agents
    Bunz, F
    Hwang, PM
    Torrance, C
    Waldman, T
    Zhang, YG
    Dillehay, L
    Williams, J
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) : 263 - 269
  • [10] Mismatch repair proficiency and in vitro response to 5-fluorouracil
    Carethers, JM
    Chauhan, DP
    Fink, D
    Nebel, S
    Bresalier, RS
    Howell, SB
    Boland, CR
    [J]. GASTROENTEROLOGY, 1999, 117 (01) : 123 - 131